Hemostemix Inc. (“Hemostemix”) (TSX Venture:HEM; OTCQB:HMTXF) is a publicly traded clinical-stage biotech company that develops and commercializes blood-derived stem cell therapies for medical conditions lacking adequate treatment options. Importantly, it is one of the first clinical-stage biotech companies to test a stem cell therapy within an international, multi-center Phase II clinical trial for patients with critical limb ischemia (“CLI”). CLI is a severe form of peripheral artery disease (“PAD”) that is caused by reduced blood flow to the extremities. After showing promising results in a Phase I trial and with a large number of historical patient treatments performed in open trials, Hemostemix’s Phase II trial targets a participant’s diseased tissue with proprietary cells grown from his or her blood that can support the formation of new blood vessels. This lead cell therapy product is called ACP-01. [Read more…]
BioInformant's Founder, Cade Hildreth, has interviewed hundreds of key opinion leaders (KOL's) from across the stem cell industry.
Rhemastem, Leveraging Stem Cells from Solid Tumors in the Race to Cure Colorectal Cancer
Headquartered in Monza, Italy, RhemaStem is a unique biotech company that specializes in developing innovative and effective drugs for colorectal cancer and other solid cancers. The company’s mission is to cure colorectal cancer and other solid cancers using its expertise in the area of cancer and normal stem cells. I had the distinct honour of interviewing Dr. Zeni of RhemaStem.
In this interview, we explore the founding of Rhemstem, its unique technology platform, intellectual property (IP), future directions, and more. Enjoy! [Read more…]
New Frontiers in Gene-Editing and Stem Cell Innovation – Interview with Dr. Chen-Tsai of Applied StemCell
I had the honor of interviewing Dr. Ruby Yanru Chen-Tsai, Chief Scientific Officer and Co-founder of Applied StemCell Inc. (ASC), a fast growing biotechnology company in Milpitas, California. Specializing in gene-editing technologies and stem cell innovation, ASC offers an optimized series of tools for basic research study, drug discovery, bio-processing, bio-production and preclinical applications.
In this fascinating interview, we discuss Dr. Yanru Chen-Tsai’s impressive background, ASC’s unique product portfolio, its TARGATT™ gene editing technology, and the company’s future trajectory. [Read more…]
LifeCell International, India’s Largest Cord Blood Bank
LifeCell is India’s largest cord blood bank, offering stem cell banking services and diagnostic testing. Established in 2004, its BabyCord program is one of the largest cord blood banking programs in the region, with 50,000+ parents preserving newborn stem cells each year and 375,000 units cryopreserved.
I had the honor of interviewing Mr. Mayur Abhaya Srisrimal, Chief Executive Officer and Managing Director of LifeCell. Mr. Abhaya has led LifeCell since 2008 and been instrumental in expanding its stem cell storage services across India with its BabyCord program. Under his leadership, LifeCell also raised growth capital from Helion Ventures and extended its preventive diagnostic services by launching BabyShield, a program targeted at reducing the infant mortality ratio. [Read more…]
Minerva Biotechnologies, Interview with CEO Dr. Cynthia Bamdad
Minerva Biotechnologies is a regenerative medicine company specializing in stem cell therapeutics that is developing cancer immunotherapies to target 75% of solid tumors and to prevent cancer metastasis. I had the honor of interviewing Cynthia Bamdad, PhD, CEO of Minerva Biotechnologies.
In this interview, we discuss Minerva’s technology platform, product portfolio, IP strategy, and strategic goals. We also explore the significance of the company’s AlphaSTEM™ Culture System that is a simple method for inducing the naïve state in human stem cells. Enjoy. [Read more…]
